|
|
|
|
Дата |
|---|
| 22:27 |
| 23.06.2026 |
| 22.06.2026 |
| 18.06.2026 |
| 17.06.2026 |
| 16.06.2026 |
| 15.06.2026 |
| 12.06.2026 |
| 11.06.2026 |
| 10.06.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
4.90
|
4.97
|
4.26
|
4.24
|
5.15
|
4.935
|
|
|
935 552.34
|
3 686.00
|
|
4.13
|
4.59
|
4.06
|
4.025
|
4.445
|
4.23
|
|
|
482 837.03
|
2 662.00
|
|
4.08
|
4.18
|
3.96
|
3.905
|
4.095
|
4.08
|
|
|
414 709.53
|
1 697.00
|
|
3.70
|
4.00
|
3.90
|
3.71
|
3.98
|
3.93
|
|
|
595 067.70
|
1 679.00
|
|
3.70
|
3.96
|
3.85
|
3.645
|
3.95
|
3.82
|
|
|
334 536.07
|
1 576.00
|
|
3.72
|
4.18
|
3.85
|
3.72
|
3.9985
|
3.72
|
|
|
409 080.13
|
1 807.00
|
|
3.69
|
4.29
|
3.90
|
3.81
|
4.10
|
3.84
|
|
|
807 852.45
|
2 823.00
|
|
3.82
|
3.96
|
3.64
|
3.6015
|
3.95
|
3.90
|
|
|
495 828.13
|
2 296.00
|
|
3.35
|
4.44
|
3.51
|
3.40
|
3.66
|
3.64
|
|
|
328 006.79
|
1 906.00
|
|
3.37
|
4.44
|
3.56
|
3.48
|
3.69
|
3.48
|
|
|
374 151.29
|
1 998.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть